Testing a new drug for advanced cancers with a specific genetic mutation

This trial tested tipifarnib, a new type of medication, in people with advanced cancers — including thyroid cancer and squamous cell cancers of the head and neck — that had a specific genetic mutation called HRAS. Researchers wanted to see if this medication could shrink or control these tumors in people whose cancers had stopped responding to standard treatments or could not be cured with surgery. The trial enrolled patients into three separate groups depending on their cancer type.

Many people with advanced squamous cell cancers and certain genetic mutations run out of effective treatment options. This medication was designed to target cancers with HRAS mutations specifically, offering hope to patients for whom other therapies had failed.